Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6071)
All Articles published online
|
Publishing Process of This Article
|
Nov 6, 2020 (publication date) through Jun 6, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Okajima M, Takahashi Y, Kaji T, Ogawa N, Mouri H. Nafamostat mesylate-induced hyperkalemia in critically ill patients with COVID-19: Four case reports. World J Clin Cases 2020; 8(21): 5320-5325 [PMID: 33269265 DOI: 10.12998/wjcc.v8.i21.5320] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v8/i21/5320.htm |
| Number | Citing Articles |
| 1 |
Hong-Long Ji, Brant M. Wagener, Timothy J. Ness, Runzhen Zhao. Fibrinolytic or anti-plasmin (nafamostat) therapy for COVID-19: A timing challenge for clinicians. Pulmonary Pharmacology & Therapeutics 2021; 70: 102055 doi: 10.1016/j.pupt.2021.102055
|
| 2 |
Maria Monticelli, Bruno Hay Mele, Elisa Benetti, Chiara Fallerini, Margherita Baldassarri, Simone Furini, Elisa Frullanti, Francesca Mari, Giuseppina Andreotti, Maria Cubellis, Alessandra Renieri. Protective Role of a TMPRSS2 Variant on Severe COVID-19 Outcome in Young Males and Elderly Women. Genes 2021; 12(4): 596 doi: 10.3390/genes12040596
|
| 3 |
Brian F. Niemeyer, Kambez H. Benam. Untapping host-targeting cross-protective efficacy of anticoagulants against SARS-CoV-2. Pharmacology & Therapeutics 2022; 233: 108027 doi: 10.1016/j.pharmthera.2021.108027
|
| 4 |
María Patricia Hernández-Mitre, Steven Y. C. Tong, Justin T. Denholm, Gregory J. Dore, Asha C. Bowen, Sharon R. Lewin, Balasubramanian Venkatesh, Thomas E. Hills, Zoe McQuilten, David L. Paterson, Susan C. Morpeth, Jason A. Roberts. Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review. Clinical Pharmacokinetics 2022; 61(10): 1331 doi: 10.1007/s40262-022-01170-x
|
| 5 |
Joseph M. Sweeney, Mohammad Barouqa, Gregory J. Krause, Jesus D. Gonzalez-Lugo, Shafia Rahman, Morayma Reyes Gil. Low ADAMTS13 Activity Correlates with Increased Mortality in COVID-19 Patients. TH Open 2021; 5(01): e89 doi: 10.1055/s-0041-1723784
|
| 6 |
Yao Lin, Yiming Shao, Yuchun Liu, Ruoxuan Yang, Shuanglin Liao, Shuai Yang, Mingwei Xu, Junbing He. Efficacy and safety of nafamostat mesilate anticoagulation in blood purification treatment of critically ill patients: a systematic review and meta-analysis. Renal Failure 2022; 44(1): 1264 doi: 10.1080/0886022X.2022.2105233
|
| 7 |
Anuja Rasarathnam, Terrence Haynes‐Smith, Wassif S. Wassif, Michael S. Dodd. Haematological and biochemical pathology markers for a predictive model for ITU admission and death from COVID‐19: A retrospective study. eJHaem 2022; 3(3): 660 doi: 10.1002/jha2.529
|
| 8 |
Abdullah All Jaber, Zeshan Mahmud Chowdhury, Arittra Bhattacharjee, Muntahi Mourin, Chaman Ara Keya, Zaied Ahmed Bhuyan. Microsecond molecular dynamics simulations revealed the inhibitory potency of amiloride analogs against SARS-CoV-2 E viroporin. Genomics & Informatics 2021; 19(4): e48 doi: 10.5808/gi.21040
|
| 9 |
Kentaro Kodama, Toru Imai, Yasuo Asai, Yutaka Kozu, Kentaro Hayashi, Tetsuo Shimizu, Yasuhiro Gon, Susumu Ootsuka. Incidence and risk factors for hyperkalaemia in patients treated for COVID‐19 with nafamostat mesylate. Journal of Clinical Pharmacy and Therapeutics 2022; 47(7): 1070 doi: 10.1111/jcpt.13646
|
| 10 |
María Patricia Hernández-Mitre, Susan C. Morpeth, Balasubramanian Venkatesh, Thomas E. Hills, Joshua Davis, Robert K. Mahar, Grace McPhee, Mark Jones, James Totterdell, Steven Y.C. Tong, Jason A. Roberts. TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate. Clinical Microbiology and Infection 2024; 30(6): 743 doi: 10.1016/j.cmi.2024.01.029
|
| 11 |
Tomomi Soma, Kentaro Fujii, Ayumi Yoshifuji, Taketomo Maruki, Kazuto Itoh, Daisuke Taniyama, Takahide Kikuchi, Naoki Hasegawa, Morio Nakamura. Nafamostat Mesylate Monotherapy in Patients with Moderate COVID-19: a Single-Center, Retrospective Study. Japanese Journal of Infectious Diseases 2022; 75(5): 484 doi: 10.7883/yoken.JJID.2021.699
|
| 12 |
Susan C. Morpeth, Balasubramanian Venkatesh, James A. Totterdell, Grace M. McPhee, Robert K. Mahar, Mark Jones, Methma Bandara, Lauren A. Barina, Bhupendra K. Basnet, Asha C. Bowen, Andrew J. Burke, Belinda Cochrane, Justin T. Denholm, Ashesh Dhungana, Gregory J. Dore, Ravindra Dotel, Eamon Duffy, Jack Dummer, Hong Foo, Timothy L. Gilbey, Naomi E. Hammond, Bernard J. Hudson, Vivekanand Jha, Purnima R. Jevaji, Oommen John, Rajesh Joshi, Gagandeep Kang, Baldeep Kaur, Seungtaek Kim, Santa Kumar Das, Jillian S.Y. Lau, Roberta Littleford, Julie A. Marsh, Ian C. Marschner, Gail Matthews, Michael J. Maze, Colin J. McArthur, James D. McFadyen, James H. McMahon, Zoe K. McQuilten, James Molton, Jocelyn M. Mora, Vijaybabu Mudaliar, Vi Nguyen, Matthew V.N. O’Sullivan, Suman Pant, Jaha E. Park, David L. Paterson, David J. Price, Nigel Raymond, Megan A. Rees, James O. Robinson, Benjamin A. Rogers, Wang-Shick Ryu, Joe Sasadeusz, Omar Shum, Thomas L. Snelling, Christine Sommerville, Nanette Trask, Sharon R. Lewin, Thomas E. Hills, Joshua S. Davis, Jason A. Roberts, Steven Y.C. Tong. A Randomized Trial of Nafamostat for Covid-19. NEJM Evidence 2023; 2(11) doi: 10.1056/EVIDoa2300132
|
| 13 |
|
| 14 |
Akeberegn Gorems Ayele, Engidaw Fentahun Enyew, Zemene Demelash Kifle. Roles of existing drug and drug targets for COVID-19 management. Metabolism Open 2021; 11: 100103 doi: 10.1016/j.metop.2021.100103
|
| 15 |
Ernest Oduro‐Kwateng, Mahmoud E. Soliman. DON/DRP‐104 as potent serine protease inhibitors implicated in SARS‐CoV‐2 infection: Comparative binding modes with human TMPRSS2 and novel therapeutic approach. Journal of Cellular Biochemistry 2024; doi: 10.1002/jcb.30528
|
| 16 |
Helen C. Causton. SARS-CoV2 Infection and the Importance of Potassium Balance. Frontiers in Medicine 2021; 8 doi: 10.3389/fmed.2021.744697
|
| 17 |
Shinya Yamada, Hidesaku Asakura. Coagulopathy and Fibrinolytic Pathophysiology in COVID-19 and SARS-CoV-2 Vaccination. International Journal of Molecular Sciences 2022; 23(6): 3338 doi: 10.3390/ijms23063338
|
| 18 |
Kaiming Tao, Philip L. Tzou, Janin Nouhin, Hector Bonilla, Prasanna Jagannathan, Robert W. Shafer. SARS-CoV-2 Antiviral Therapy. Clinical Microbiology Reviews 2021; 34(4) doi: 10.1128/CMR.00109-21
|